Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN FRANCISCO AND BOSTON, MAY 28, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES.

APOGEE THERAPEUTICS TO PARTICIPATE IN UPCOMING JUNE CONFERENCES

UP TO $1.3 BILLION IN FLEXIBLE, NON-DILUTIVE CAPITAL, INCLUDING UP TO $800 MILLION OF SYNTHETIC ROYALTY AND ACCESS OF UP TO $500 MILLION IN SENIOR CORPORATE DEBT

APOGEE THERAPEUTICS ANNOUNCES $1.3 BILLION STRATEGIC FINANCING COLLABORATION WITH BLACKSTONE LIFE SCIENCES TO ADVANCE PHASE 3 DEVELOPMENT AND COMMERCIALIZATION OF ZUMILOKIBART

APEX PART B MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE; MID-DOSE ZUMILOKIBART PLANNED TO ADVANCE INTO PHASE 3 TRIALS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD) IN 2H 2026

APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK PART B INDUCTION DOSE OPTIMIZATION RESULTS FROM PHASE 2 APEX TRIAL OF ZUMILOKIBART IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

SAN FRANCISCO AND BOSTON, MAY 26, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED IT WILL REPORT PART B 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART ON WEDNESDAY, MAY 27, 2026. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT PART B 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ON MAY 27, 2026

ZUMILOKIBART ADVANCING ACROSS MULTIPLE INDICATIONS, WITH PHASE 3 INITIATION IN ATOPIC DERMATITIS (AD) EXPECTED LATER THIS YEAR: - APEX PHASE 2 PART A 52-WEEK DATA DEMONSTRATED DURABLE MAINTENANCE AND IMPROVED EFFICACY OVER TIME WITH EVERY 3- AND 6-MONTH DOSING IN MODERATE-TO-SEVERE AD - APEX PHASE 2 PART B 16-WEEK DATA IN AD EXPECTED IN Q2 2026 - FOLLOWING POSITIVE PHASE 1B ASTHMA RESULTS EARLIER THIS YEAR, EXPANSION PLANS ARE UNDERWAY WITH ADDITIONAL TRIAL DETAILS FOR ASTHMA AND EOSINOPHILIC ESOPHAGITIS (EOE) EXPECTED LATER THIS YEAR STRONG CASH POSITION OF $1.3B FOLLOWING SUCCESSFUL PUBLIC EQUITY OFFERING EXTENDING RUNWAY INTO 2029, THROUGH PLANNED BLA FILING FOR AD, SUBJECT TO REGULATORY ALIGNMENT SAN FRANCISCO AND BOSTON, MAY 11, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY PROVIDED PIPELINE PROGRESS AND REPORTED FIRST QUARTER 2026 FINANCIAL RESULTS. WE ARE OFF TO A RAPID START IN 2026, REFLECTING THE TEAM'S RELENTLESS FOCUS ON EXECUTION.

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SAN FRANCISCO AND BOSTON, MARCH 26, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,750,000 SHARES OF ITS COMMON STOCK, INCLUDING THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE UP TO 750,000 ADDITIONAL SHARES, AT A PUBLIC OFFERING PRICE PER SHARE OF $70.00. THE AGGREGATE GROSS PROCEEDS TO APOGEE FROM THE OFFERING WERE APPROXIMATELY $403 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY APOGEE.

APOGEE THERAPEUTICS, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES FOR GROSS PROCEEDS OF $403 MILLION

SAN FRANCISCO AND BOSTON, MARCH 24, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,000,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE PER SHARE OF $70.00. THE AGGREGATE GROSS PROCEEDS TO APOGEE FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $350 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY APOGEE. THE OFFERING IS EXPECTED TO CLOSE ON MARCH 26, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. IN ADDITION, APOGEE HAS GRANTED THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 750,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

APOGEE THERAPEUTICS, INC. ANNOUNCES PRICING OF $350 MILLION UNDERWRITTEN PUBLIC OFFERING

SAN FRANCISCO AND BOSTON, MARCH 23, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION OF SHARES OF ITS COMMON STOCK. IN ADDITION, APOGEE EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $45 MILLION OF SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED PUBLIC OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING. ALL OF THE SHARES OF COMMON STOCK ARE BEING OFFERED BY APOGEE.

APOGEE THERAPEUTICS, INC. ANNOUNCES PROPOSED $300 MILLION UNDERWRITTEN PUBLIC OFFERING

APEX PART A DATA DEMONSTRATED DURABLE MAINTENANCE OF RESPONSE AT 52-WEEKS FOR EVERY 3- AND 6-MONTHS DOSING, RESPECTIVELY, INCLUDING: - 75% AND 85% PATIENTS MAINTAINED EASI-75 - 86% AND 78% PATIENTS MAINTAINED VIGA 0/1 DEEPENING OF RESPONSE WAS OBSERVED ACROSS ALL LESIONAL AND ITCH ENDPOINTS WITH BOTH EVERY 3- AND 6- MONTH DOSING AMONG THE FULL POPULATION OF PATIENTS INITIALLY RANDOMIZED TO ZUMILOKIBART

APOGEE THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 PART A 52-WEEK DATA OF ZUMILOKIBART (APG777), DEMONSTRATING MAINTENANCE AND DEEPENING OF RESPONSES WITH EVERY 3- AND 6-MONTH DOSING IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

SAN FRANCISCO AND BOSTON, MARCH 22, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED IT WILL REPORT PART A 52-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART ON MONDAY, MARCH 23, 2026. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT PART A 52-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART (APG777) IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ON MARCH 23, 2026

Apogee Therapeutics, Inc.

APGE

Price

Financial Reports

No items found.

Press Releases

Apogee Therapeutics, Inc.

APGE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

APGE